Project description DEENESFRITPL A novel drug against rheumatoid arthritis Rheumatoid arthritis (RA) is an autoimmune condition associated with pain and stiffness in the joints caused by inflammation. The aim of the EU-funded RheumArth project is to introduce the novel AP1189 drug for clinical validation. AP1189 is an agonist against melanocortin receptors, which apart from regulating skin pigmentation also seem to inhibit inflammation. The idea is to use AP1189 to promote the resolution of RA inflammation. The promising preliminary clinical data with regards to safety have set the stage for validating the clinical efficacy of the AP1189 drug in RA patients. Show the project objective Hide the project objective Objective Rheumatoid arthritis (RA) is a chronic autoimmune disorder causing inflammation and permanent damage in joints and surrounding tissues - leading to severe disability, decreased quality of life, and reduced life expectancy. The disease affects more than 6 million people with annual costs amounting to €45billion in the Europe (EU) alone. There is a wide range of drug therapies for RA, mobilizing a variety of anti-inflammatory and immune modulating effects. However, a significant proportion (30%) of the patients do not respond to current treatments, efficacy is often reduced over time and the incidence of side effects is high and can be severe and life threatening.AP1189 is new chemically-synthesized small molecule drug for the treatment of Rheumatoid arthritis (RA). Through specific activation of the patients’ self-anti-inflammatory mechanisms, our first drug candidate renders unprecedent combination of safety, effectiveness and patient compliance, without the side effects associated with current therapies. The clinical validation of our drug for RA - 1st indication (foreseen for the Innovation Project) - will not only open a large market within this therapeutic area, as it will allow Synact to set a market foothold in the chronic inflammatory disease market, supporting the company´s medium term strategic positioning as an unique provider of a new generation of anti-inflammatory drugs. AP1189 clinical validation is on-going with current Phase I clinical trials showing promising preliminary results – safety and tolerance was proved in healthy human volunteers. Next step in the development will be a Phase IIa Proof-Of-Concept (POC) trail to validate our drug´s efficacy profile in RA patients. In this context, the present Phase 1 will be of utmost importance to validate AP1189´s market position and potential in RA and prepare the large clinical validation aimed for in the ensuing SME Instrument Phase II project. Fields of science medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesclinical medicinerheumatologymedical and health scienceshealth sciencesinflammatory diseases Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator SYNACT PHARMA APS Net EU contribution € 50 000,00 Address DRONNINGGARDS ALLE 136 2840 HOLTE Denmark See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Danmark Hovedstaden Nordsjælland Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 71 429,00
